Clinical Trials
7 trialsNCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT04755920 2024-05-09
SGM-CBM
Leiden University Medical Center
Phase 2 Recruiting
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT00643890 2012-02-22
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Neurologix, Inc.
Phase 2 Terminated
NCT00906516 2009-05-21
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals Inc.
Phase 2 Unknown